Northern Ireland pharmaceutical company Warner Chilcott, previously known as Galen Holdings PLC, has announced its latest quarterly results for the period ended June 30.

Warner Chilcott has announced that it has received a decision from the United States District Court for the Southern District of Indiana concerning its patent litigation dispute with Teva Pharmaceuticals (Teva).

GALEN HOLDINGS plans to complete its metamorphosis from an Irish pharmaceuticals group into a company focused on the US by changing its name to Warner Chilcott.

Pharmaceutical company Galen has seen pre-tax profits double to $48m (€40.38m) in Q2 and directors are to recommend a name change to shareholders at year's end to Warner Chilcott PLC.

Speciality pharmaceutical company Galen Holdings has sold its UK pharmaceutical product sales and marketing business for £40m (€59.8m).

Craigavon-based pharmaceutical firm Galen has settled its patent litigation with Barr Pharmaceuticals.

The chief executive of Northern Ireland pharmaceutical company Galen Holdings, Roger Boissonneault, has sold off most of his shares in the company for just over $3m (€2.48m).

Northern Ireland pharmaceutical company Galen Holdings said today it has won three-year exclusivity for its Ovcon product.

GALEN founder Allen McClay’s personal spending spree on acquiring company assets rose to €277m yesterday when he spent €34m buying Galen’s Pharmaceutical Development and Manufacturing Services business (PDMS).

THE world’s first chewable contraceptive, developed by Irish pharmaceutical company Galen, has won approval from the US Food and Drug Administration.

The US Food & Drug Administration has given final approval to a new form of oral contraceptive - Ovcon - manufactured by Northern Ireland speciality pharmaceutical company Galen Holdings.

SHARES in Galen Holdings increased by 3.81% yesterday after the company announced better-than-expected results in its final quarter.

Galen reported today that full-year total pharmaceutical product revenues increased by 84% to $432.3m (€375m) from $235.2m (€204m) to beat analysts’ forecasts.

Northern Ireland-based pharmaceuticals group Galen toasted the addition of a string of new drugs today after third quarter results showed sales had more than doubled.

Pharmaceuticals group Galen was confident about its prospects today after seeing record sales of $157.9m (€137.2m) in the six months to March 31.

GALEN has received regulatory approval for its new menopause drug Femring.

Pharmaceutical firm Galen cheered investors today after it emerged its hormone replacement treatment had been given the thumbs up by US regulators.